Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
Update: 2025-10-28
Description
In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to expand its antibody-drug conjugate portfolio, and new guidance from the American College of Surgeons classifying obesity as a treatable condition.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
